COVID-19 pandemic
Bahrain's National Health Regulatory Authority approves the registration of the BBIBP-CorV vaccine developed by Sinopharm after Phase III clinical trials results showed an 86% efficacy rate.
Sources: Gulf News
Changes
- Bahrain's National Health Regulatory Authority approves the registration of BBIBP-CorV developed by Sinopharm after a data from Phase III clinical trials which the country had participated showed an 86% efficacy rate.
- Bahrain's National Health Regulatory Authority approves the registration of the BBIBP-CorV vaccine developed by Sinopharm after Phase III clinical trials results showed an 86% efficacy rate.